Business
Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test
500,000 Rapid Tests Cleared for Shipment to Company's WarehouseENGLEWOOD, CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"500,000 Rapid Tests Cleared for Shipment to Company's WarehouseENGLEWOOD, CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the \"Company\"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation of export approval for product shipment by China's Ministry of Commerce for the Company's COVID-19 IgG/IgM Rapid Test.Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, \"The backlog of medical products being exported from China created a shipment delay, but Aytu's next 500,000 rapid tests have now been cleared for shipment to the U.S. This export clearance from China, along with the additional supply we have secured through our new relationship with Biolidics, gives us great confidence in our supply chain and ability to provide these needed test kits to the U.S. medical community. Our shipments remain on track for delivery and, upon receipt, will be distributed to U.S. customers.\"About Aytu BioScience, Inc.Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or \"Low T\"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid...